Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With OTC Cialis Rights, Sanofi Launches Latest Salvo In Consumer Sector Battle

This article was originally published in The Tan Sheet

Executive Summary

Sanofi gains rights from Eli Lilly & Co. to apply for OTC approval of Cialis in the U.S., Europe, Canada and Australia. Launching the first OTC product indicated for erectile dysfunction would mark another milestone in Sanofi CEO Chris Viebacher’s mission to move the firm into the neighborhood of global OTC leaders.

You may also be interested in...



Cialis Or Viagra Switch? Sanofi Survey, Pfizer Help Wanted Ad Could Be Signs

Viagra marketer Pfizer also could have nonprescription sales in sight as it recruits a "global sexual health" brand manager with responsibilities including shepherding market expansion through an Rx-to-OTC switch.

Cialis Or Viagra Switch? Sanofi Survey, Pfizer Help Wanted Ad Could Be Signs

Viagra marketer Pfizer also could have nonprescription sales in sight as it recruits a "global sexual health" brand manager with responsibilities including shepherding market expansion through an Rx-to-OTC switch.

Sanofi Creates Consumer Unit With Eye To Expansion

Former Bayer executive Alan Main tapped to lead Consumer HealthCare global business unit, which Sanofi will consider expanding through acquisitions after integrating OTC brands added in a recent swap with Boehringer Ingelheim.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS106953

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel